NEXT Financial Group Inc Purchases 3,394 Shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA)

NEXT Financial Group Inc raised its position in shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) by 384.8% in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 4,276 shares of the company’s stock after purchasing an additional 3,394 shares during the quarter. NEXT Financial Group Inc’s holdings in Teva Pharmaceutical Industries were worth $39,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. MetLife Investment Advisors LLC increased its stake in Teva Pharmaceutical Industries by 20.0% during the 1st quarter. MetLife Investment Advisors LLC now owns 84,453 shares of the company’s stock valued at $1,324,000 after purchasing an additional 14,100 shares in the last quarter. Bank of Montreal Can increased its stake in Teva Pharmaceutical Industries by 7.3% during the 1st quarter. Bank of Montreal Can now owns 570,059 shares of the company’s stock valued at $8,938,000 after purchasing an additional 38,659 shares in the last quarter. Dynamic Capital Management Ltd increased its stake in Teva Pharmaceutical Industries by 59.3% during the 1st quarter. Dynamic Capital Management Ltd now owns 23,828 shares of the company’s stock valued at $374,000 after purchasing an additional 8,866 shares in the last quarter. SNS Financial Group LLC increased its stake in Teva Pharmaceutical Industries by 24.0% during the 1st quarter. SNS Financial Group LLC now owns 12,400 shares of the company’s stock valued at $194,000 after purchasing an additional 2,400 shares in the last quarter. Finally, TD Asset Management Inc. increased its stake in Teva Pharmaceutical Industries by 4.0% during the 1st quarter. TD Asset Management Inc. now owns 291,880 shares of the company’s stock valued at $4,577,000 after purchasing an additional 11,300 shares in the last quarter. Institutional investors and hedge funds own 65.69% of the company’s stock.

TEVA opened at $7.02 on Friday. The company has a debt-to-equity ratio of 1.73, a quick ratio of 0.62 and a current ratio of 0.96. The stock has a market capitalization of $7.41 billion, a P/E ratio of 2.51, a price-to-earnings-growth ratio of 0.76 and a beta of 1.64. The business has a 50 day simple moving average of $8.40. Teva Pharmaceutical Industries Ltd has a 12-month low of $6.34 and a 12-month high of $25.96.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings data on Wednesday, August 7th. The company reported $0.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.55 by $0.02. The company had revenue of $4.34 billion for the quarter, compared to the consensus estimate of $4.25 billion. Teva Pharmaceutical Industries had a negative net margin of 21.94% and a positive return on equity of 16.04%. The firm’s revenue was down 7.7% compared to the same quarter last year. During the same quarter last year, the firm posted $0.78 earnings per share. As a group, research analysts predict that Teva Pharmaceutical Industries Ltd will post 2.26 EPS for the current fiscal year.

In other Teva Pharmaceutical Industries news, VP Notaristefani Carlo De sold 16,070 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Monday, May 20th. The shares were sold at an average price of $11.42, for a total transaction of $183,519.40. Following the transaction, the vice president now owns 49,659 shares of the company’s stock, valued at $567,105.78. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Sol J. Barer purchased 111,000 shares of the stock in a transaction on Monday, June 3rd. The shares were purchased at an average cost of $8.98 per share, for a total transaction of $996,780.00. Following the acquisition, the director now directly owns 115,942 shares of the company’s stock, valued at $1,041,159.16. The disclosure for this purchase can be found here. Company insiders own 0.49% of the company’s stock.

A number of analysts have weighed in on TEVA shares. UBS Group lowered shares of Teva Pharmaceutical Industries from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $22.00 to $12.00 in a research note on Tuesday, May 28th. Bank of America lowered shares of Teva Pharmaceutical Industries from a “buy” rating to an “underperform” rating and reduced their price target for the stock from $19.00 to $9.00 in a research note on Thursday, May 30th. Sanford C. Bernstein reduced their price target on shares of Teva Pharmaceutical Industries from $17.00 to $11.00 and set a “market perform” rating for the company in a research note on Tuesday, June 18th. They noted that the move was a valuation call. Raymond James reduced their price target on shares of Teva Pharmaceutical Industries from $22.00 to $15.00 and set an “outperform” rating for the company in a research note on Thursday. Finally, BMO Capital Markets reduced their price target on shares of Teva Pharmaceutical Industries from $11.00 to $9.00 and set a “market perform” rating for the company in a research note on Friday. Six analysts have rated the stock with a sell rating, fourteen have given a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Hold” and an average price target of $13.21.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Recommended Story: What is the Fibonacci sequence?

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd (NYSE:TEVA).

Institutional Ownership by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.